Browse > Article
http://dx.doi.org/10.14476/jomp.2019.44.1.11

The Effect of Dilution with 10% Dextrose Solution on the Potency of Botulinum Toxin A  

Ham, Jong Wook (Department of Orthodontics and Cosmetic Dentistry, Dr. Ham's Dental and Botulinum Toxin Clinic)
Kwon, Jeong-Seung (Department of Orofacial Pain and Oral Medicine, Yonsei Dental Hospital, Yonsei University College of Dentistry)
Cho, Eunae Sandra (Department of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry)
Choi, Jong Hoon (Department of Orofacial Pain and Oral Medicine, Yonsei Dental Hospital, Yonsei University College of Dentistry)
Publication Information
Journal of Oral Medicine and Pain / v.44, no.1, 2019 , pp. 11-15 More about this Journal
Abstract
Purpose: The aim of this study was to compare the potency-stabilizing effects of two different diluents of botulinum toxin A (10% dextrose solution and 0.9% saline). Methods: A mouse lethality bioassay was undertaken. Ninety mice were divided into experimental and control groups which received varying dosages in subgroups of 10. The experimental group was injected with botulinum toxin A diluted with 10% dextrose solution and the control group was injected with botulinum toxin A diluted with 0.9% saline. A 72 hours after intraperitoneal injection, the number of dead mice was counted to confirm median lethal dose ($LD_{50}$) of each group. Results: The value of $LD_{50}$ in the experimental group was approximately 0.131 mL (1.31 U) and the value of $LD_{50}$ in the control group was approximately 0.107 mL (1.07 U). The potency preservation rate of the experimental group was estimated to be 93.5% and that of the control group was estimated to be 76.3%. Conclusions: Dilution with 10% dextrose solution displayed less potency loss than 0.9% saline.
Keywords
Botulinum toxins; Type A; Glucose; Saline solution;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-140.   DOI
2 Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-253.   DOI
3 Yun JH, Ham JW, Park JE, Kim CK. Experimental study on the potency-maintaining periods of reconstituted botulinum type A toxin. J Korean Dent Assoc 2005;43:119-125.
4 Kazim NA, Black EH. Botox: shaken, not stirred. Ophthalmic Plast Reconstr Surg 2008;24:10-12.   DOI
5 Trindade De Almeida AR, Kadunc BV, Di Chiacchio N, Neto DR. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 2003;29:530-531; discussion 532.   DOI
6 Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1-60.   DOI
7 Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.   DOI
8 Cichon JV Jr, McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 1995;105:144-148.   DOI
9 Ekong TA, Feavers IM, Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 1997;143:3337-3347.   DOI
10 Sesardic D, McLellan K, Ekong TA, Das RG. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996;78:283-288.   DOI
11 Ghosh MN. Fundamentals of experimental pharmacology. 2nd ed. Calcutta: Scientific Book Agency; 1984. pp. 187-189.
12 Kim JY, Kim ST, Cho SW, Jung HS, Park KT, Son HK. Growth effects of botulinum toxin type A injected into masseter muscle on a developing rat mandible. Oral Dis 2008;14:626-632.   DOI
13 Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-770.
14 Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-985.   DOI
15 Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.   DOI
16 Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 1992;58:3426-3428.   DOI
17 Randhawa MA. Calculation of LD50 values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad 2009;21:184-185.
18 Finney DJ. Probit analysis. 2nd ed. Cambridge: Cambridge University Press; 1952.
19 Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg 1996;22:39-43.   DOI